You are using an out of date browser. It may not display this or other websites correctly. You should upgrade or use an alternative browser.
Immunogenicity is a major problem with protein-based therapeutics due to circulating anti-drug antibody (ADA) production. ADA may lead to many clinical problems including allergic reactions, altered pharmacokinetic, reduced efficacy, etc. Thus, perform an immunogenicity testing to evaluate the ADA level induced by therapeutic protein drug is a necessary step in both clinical studies and post marketing clinical monitoring.
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.